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f outpatient Administration 
I of Paclitaxel 
r 
Introduction Recent review of the published phase 
paclitaxel (Taxol®, Bristol-Meyers I trials of paclitaxel suggests that the ad-
Squibb), anti neoplastic agent made from ministration of premedications may play 
the bark of the Pacific yew tree, is un- a more important role in reducing the 
doubted ly one of the most exciting agents occurrence of severe hypersensitivity re-
to be evaluated over the past decade. action than the dosing schedule itself. 
paclitaxel has demonstrated significant This observation is supported by a large 
promise against ovarian and metastatic randomized trial which compared two 
breast cancer, and appears to be the most .,_doses of paclitaxel (175 and 135 mg/m2) 
effective single agent to date for non- and two schedules (24 and three hours) 
small-cell lung cancer in trials conducted using a bifactorial design. The incidence 
by Eastern Cooperative Oncology Group of severe hypersensitivity reactions was 
(ECOG). 1 .2% with the longer infusion and 2.2% 
The toxicities of paclitaxel include 
myelosuppression, neuropathy, cardiac 
arrhythmias, and hypersensitivity reac-
tions. Based on initial observations sug-
gesting that the incidence of hypersensi-
tivity reactions may be higher with the 
shorter infusion durations, later trials were 
developed using 24-hour infusions and 
prophylactic antiallergic regimens. Us-
ing this method of administration, which 
generally requires an inpatient hospital 
admission, the incidence of hypersensi-
tivity reactions was approximately 3%. 
In this article, we will examine the 
results of ongoing trials using a shorter 
three-hour infusion time of paclitaxel giv-
en at various doses and focus on the issues 
of dosing and safety, efficacy, and meth-
od of administration thus alleviating the 
need for inpatient hospital admission and 
thereby maximizing the cost effective-
ness of this drug therapy. 
Dosing and Safety 
Severe hypersensitivity reactions were 
identified early in the course of phase I 
clinical trials of paclitaxel; the majority 
occurred in association with a short infu-
siontimeof paclitaxel (one to three hours). 
As a result of these observations, the 
length of administration was increased 
and a premedication regimen that includ-
ed steroids and hl and h2 histamine-
receptor blockers was introduced. Subse-
quent studies proved that these results 
Were safe. 
Paclitaxel has 
de1nonstrated 
significant prornise 
against ovarian 
and nietastatic 
breast cancer, and 
appears to be tl:Je 
rnost effective 
single agent to date 
for non-sniall-cell 
lung cancer. 
with the shorter one. Of note, there also 
was no apparent effect of dose on the 
occurrence of severe hypersensitivity re-
actions in this trial (1.4% with the higher 
dose, 1.9% with the lower). 
A recent study by Schiller et al demon-
strated that higher paclitaxel doses up to 
300 mg/m2 can be administered over 
Oncology 
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three hours with the standard 
premedications. One of 35 patients (2.8%) 
had a grade 3 anaphylactic reaction with-
in one minute of initiation of his second 
dose of 250 mg/m2 of paclitaxel requiring 
treatment with diphenhydramine, fluids, 
and oxygen. Rechallenge was not con-
ducted. Another patient developed facial 
flushing and severe headaches approxi-
mately 15 minutes following completion 
of his first cycle of 300 mg/m2 of paclitaxel. 
No treatment was given, and the patient 
received subsequent courses of pad itaxel 
at the same dose without any recurrence 
of the symptoms. The author concluded 
that with proper monitoring and pre-med-
ication, high doses of paclitaxel can be 
safely administered in the outpatient set-
ting. 
More studies are currently being con-
ducted to evaluate one-hour infusion of 
paclitaxel in combination with other 
antineoplastic agents, and the prelimi-
nary reports were published in the pro-
ceedings of the 1994 Annual Meeting of 
the American Society of Clinical 
Oncology. 
The effects of paclitaxel on the bone 
marrow, however, are dose related. lnter-
esti ng ly, the previously mentioned 
bifactorial randomized trial demonstrat-
ed striking decreases in bone marrow 
suppression associated with the three-
hour paclitaxel infusion. The short infu-
sion was associated with a 17% inci-
dence of grade 4 granulocytopenia and 
no febrile neutropenia, whereas 74% of 
the patients given pacl itaxel over 24 hours 
developed grade4 granulocytopenia and 
12% febrile neutropenia. Pharmacoki-
netic data indicated both area-under the 
curve (AUC) and Cmax values to be sub-
stantially higher when identical doses of 
paclitaxel are administered over three 
pours as compared to 24 hours. However, 
the percentage decreases in both the white 
blood cell counts and the absolute neu-
trophil counts follows an Emax model 
that relates these parameters to the dura-
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tion that the plasma concentration of 
paclitaxel is maintained about 0.1 umol/ 
L. 
Drug sequencing also plays a signifi-
cant role in toxicities when 24-hour infu-
sion of paclitaxel is combined with 
cisplatin or doxorubicin. Increased 
neutropenia and decreased paclitaxel 
clearance are observed when cisplatin is 
administered before paclitaxel regardless 
of dose. The potential mechanism is the 
inhibition of cytochrome P-450 depen-
dent paclitaxel metabolizing enzyme by 
cisplati n. Cumulative thrombo-cytopenia, 
infections, and severe mucositis become 
the dose I imiting toxicities when pacl itaxel 
125 mg/m2 24-hour infusion precedes.,_ 
doxorubicin 48 mg/m2 48-hour infusion; 
when the sequence is reversed, the doses 
of both agents can be escalated. Doxoru-
bicin level was also noted to increase by 
30% when paclitaxel was administered 
prior to doxorubicin. 
Many combination regiments using 
one-hour and three-hour paclitaxel infu-
sion in various diseases are currently un-
dergoing evaluation and were reported at 
the 1994 Annual Meeting of the Ameri-
can Society of Clinical Oncology. The 
effect of drug sequencing was not studied 
in these preliminary reports, but it is spec-
ulated that this effect in the three-hour 
infusion is probably less significant due to 
the overlapping kinetic factors. 
Peripheral sensory neuropathy can also 
occur with paclitaxel and is dose related 
but not scheduled related. Arthralgias and 
myalgias sometimes occur in association 
with peripheral neuropathy. Schiller's 
report suggested that troublesome 
arthralgias and myalgias are more prom-
inent with high doses (>250 mg/m2) ad-
ministered over three hours in compari-
son with similar doses over 24 hours and 
lower doses (210 mg/m2) overthree hours. 
In this study, 27 of 111 courses (24%) 
required narcotics for pain control. 
Prednisone also appeared to promptly 
alleviate the symptoms of many of these 
patients. 
Other side effects, such as nausea/ 
vomiting, mucositis, and diarrhea seen 
with paclitaxel administration are more 
associated with dosing than with sched-
ule effects. 
Efficacy 
The key question surrounding both the 
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Table 1. 
Manifestations and Recommended Management of 
Hypersensitivity Reaction Associated with Paclitaxel Infusion 
Major manifestations: 
Other manifestations: 
Recommended 
premedications: 
Recommended 
precautions: 
Recommended 
treatment: 
Recommended 
rechallenge: 
• Respiratory distress + bronchospasm, hypotension, 
angioedema 
• Flushing, urticaria, rashes, chest and extremity pains 
• Dexamethasone 20 mg IV or PO at -12 and -6 hour 
• Diphenhydramine 50 mg IV at -30 min 
• Cimetidine 300 mg or ranitidine 50 mg IV at -30 min 
• Medical personnel should be available (especially for 
the first two treatments) 
• Emergency equipment, fluids, pressors, and other 
injectable drugs (e.g., epinephrine, diphenhydramine, 
steroids) close to bedside 
Major manifestations: 
• discontinue paclitaxel immediately 
• diphenhydramine 25-50 mg IV as indicated 
• pressors, fluids, epinephrine as indicated 
• dexamethasone 20 mg IV every 6 hours for persistent 
symptoms 
Minor manifestations: 
" diphenhydramine 50 mg IV every 4 to 6 hours as 
indicated 
• symptomatic treatment 
• Dexamethasone 20 mg IV every 6 hours for 4 doses 
(may begin as soon as patient is stabilized); the last 
dose should be given 30 mins before the rechallenge 
• Diphenhydramine 50 mg IV and cimetidine 300 mg or 
ranitidine 50 mg IV 30 mins before the rechallenge· 
• A freshly prepared solution of paclitaxel should be 
given at 10% of the rate required to deliver the solution 
over 24 hrs; this rate should be maintained for 2 hours. 
If no major reaction occurs, the rate should be in-
creased gradually over the next 6 hours to the original 
24-hour rate. If the original HSR occurred after a 
negligible dose of paclitaxel, the full does should be 
readministered. If a substantial fraction of the dose was 
infused before the HSR, the rechallenge dose should be 
the remaining dose fraction. Medical personnel should 
be available. 
dose and the schedule issues of paclitaxel 
is the effect on antitumor efficacy. At the 
present time, efficacy data comparing 
different infusion durations are available 
from only one clinical trial. National Can-
cer Institute of Canada (NCIC)/European 
investigators randomized patients with 
platinum-pre-treated ovarian cancer in a 
2x2 factorial design to one of two doses of 
paclitaxel, 135 and 175 mg/m2 , and one 
of two infusion durations, three or 24 
hours. Neither response rates (17% vs 
20%) nor survival rates differed for pa-
tients on the three- and 24-hour arms. 
However, the 24-hour schedule was as-
sociated with substantially more grade 4 
neutropenia (7 4% vs 17%) and a higher 
incidence of febrile neutropenia (12% vs 
0%). Thus, only 76.5% of patients in the 
24-hour group received at least 90% of 
the planned dose as compared with 92% 
in the three-hour arm. 
One question which needs to be ad-
dressed is whether the support of granulo-
cyte colony-stimulating factor(G-CSF) will 
allow maintenance of chemotherapy 
dose-intensity of the 24-hour arm. The 
Gynecology Oncology Group (COG) is 
currently conducting a randomized phase 
Ill trial in ovarian cancer addressing the 
role of G-CSF with a 24-hour infusion of 
high dose paclitaxel (250 mg/m2 ) with the 
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~~~~ercially Available Administration Sets for Delivery of Paclitaxel 
/. Institutional Administration 
catalog Number Description Type of Pump 
ABBOTT (1-800-222-6883) 
11140-48 Proximal set Omni-Flow 
4000 series 
1736-48 
2427-02 
1772-01 
9252-68 
(container to pump) + 
Distal extension set 
· (pump to patient) 
Vented dual channel set · 
Vented set 
Vented set 
Lifecare 5000 plus 
Lifecare Macro 
(flow rate 999ml/hr) 
Lifecare Macro 
(flow rate 99.9ml/hr) 
BAXTER (1-800-933-0303) .. ,_ 
2C1042 Vented Set Flo-Guard 8000 series 
1(8355S Vented with in-line filter Flo-Guard 6000 series 
!MED (1-800-854-2033) 
2260 
2262 
2264 
9630 
9635 
JVAC (1-800-854-7128) 
59953 
C20350 
Vented Set 
Non-vented set 
Vented set with 
in-line filter 
Vented set 
Non-vented set 
Gemini PC 1 & 2 
Gemini PC 1 & 2 
Gemini PC 1 & 2 
IMED 900 model 
IMED 900 model 
Vented & non-vented set IVAC 590 & 599 model 
+ extension set 14" with 
in-line filter 
MCGAW (1-800-854-6851) 
V8333 Vented & non-vented set AccuPro pump 
II. Ambulatory Infusion Pump 
ABBOTT 
Pancretec Provider 5000 
Pump 
BLOCK (1-800-944-1501) 
Verifuse Ambulatory 
Infusion Pump 
McGaw Excel 250, 500, or 1000 ml polyolefin container 
+ Abbott/McGaw adaptor (#11075) +Abbott Lifeshield 
Anesthesia Pump set-OL polyethylene-lined cartridge-
tubing set (#13503) + IVEX-HP in-line filter (#4524) 
McGaw Excel polyolefin container+ Block vented 
(V021011) or non-vented set (V021014) with 0.22 
micron filter or 
Reservoir set (V021012) = Non-PVC 120 ml container 
+tubing set 
PHARMACIA DEL TAC (1-800-426-2448) 
CADD-1, CADD-PLUS, McGaw Excel polyolefin container+ TOTM remote 
CADD-PCA reservoir adaptor cassette (#21-7016) [bag spike and 60-
inch tubing included]** 
III. Filters for Administration of Paclitaxe/ 
Catalog Number 
Abbott 4524-58 
Abbott 4521-48 
Abbott 2679-48 
Description 
IVEX-HP 
IV EX-HP 
IVEX-2 
Type of Pump 
various 
various 
various 
**in-line filter not included in the current product, may add filter at the end of tubing 
but non-luer-lock system.needs to be taken into consideration if patient is to receive 
treatment at home 
secondary goal to evaluate the dose of the 
cytokine required. Other trials in patients 
with breast and lung cancer are ongoing 
to address the efficacy of higher doses of 
paclitaxel with or without G-CSF and 
determine the impact of different admin-
istration schedules on therapeutic out-
comes. Although in-vitro data indicated 
that one-third activity was recorded with 
three-hour exposure time vs. 24-hour 
exposure time, in previously treated ova-
rian and breast cancer patients, the end-
point of the treatment is primarily pallia-
tive which makes the toxicities of the 
therapy, cost of treatment and the quality. 
of life of the patients far outweigh the 
potential differences in the response rate. 
Method of Administration 
Because of the unique nature of 
paclitaxel, with its complicated formula-
tion and potentially significant side ef-
fects, special preparation of the pacl itaxel 
infusion and monitoring of patients are 
required. 
Hypersensitivity reactions, particular-
ly anaphylactoid signs and symptoms, are 
a major concern during paclitaxel admin-
istration. The majority of the hypersensi-
tivity reactions are reported to occurwithin 
5-10 minutes of the initiation of infusion 
and during the first and second doses of 
paclitaxel. The manifestations and rec-
ommended management are listed in 
Table 1. For outpatient administration of 
paclitaxel over three hours, a test dose or 
close monitoring with recommended pre-
medications is being used. 
Prior to the availability of Dr. Schiller's 
report, three patients at our institution (11 
courses) were treated with high dose 
paclitaxel (250 mg/m2) infused over six 
hours in the outpatient infusion center. 
Al I patients were pre-treated with stan-
dard antiallergic medications and did not 
receive a test dose. All three patients 
tolerated their therapy without any com-
plications. 
Another consideration is the interac-
tion of the drug with the administration 
device. Paclitaxel is poorly soluble and 
requires a vehicle containing 
polyoxyethylated castor oil (Cremophor 
EL) which is known to leach phthalate 
plasticizers (e.g., diethlhexylphthalate 
[DEHP]) from polyvinylchloride (PVC) 
bags and administration sets. Glass or 
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polyolefin containers are recommended 
for preparation of the solution. Non-PVC 
(e.g., polyethylene-lined) tubing sets with 
an in-line 0.2 micron filter are also rec-
ommended by the National Cancer Insti-
tute. Table 2 lists the current commercial-
ly available administration sets for deliv-
·ery of paclitaxel in an institutional setting 
or via ambulatory infusion pump. 
Current stability data indicates thatthe 
drug remains chemically and physically 
stable for 48 hours at 0.3 - 1 .2 mg/ml at 
room temperature and normal fluores-
cent light. For a three-hour infusion, most 
of the solution can be diluted in 300- 500 
ml 0.9% sodium chloride or 5% dextrose. 
··-Compatibility information of paclitaxel 
solutions with other medications is mini-
mal. A recent study was published by 
Trissel and Martinez on turbidimetric as-
sessment of the compatibility of Taxol® 
with 42 other drugs during a simulated Y-
site injection. The combination of 
paclitaxel with four drugs, including 
chlorpromazine, hydroxyzine, methyl-
prednisolone and mitoxantrone, resulted 
in decreases in the inherent surfacant 
haze from the Taxol® formulation. This 
loss may indicate an interaction between 
the drugs and the formulation. Combina-
tion with amphotericin B resulted in an 
increase in turbidity which eventually 
under went separation and layering. 
Chemical stability of the drug combina-
tions mentioned above were not con-
ducted in this study. 
Local venous effects can also occur 
with administration of pad itaxel. Tender-
ness, darkening and hardness can some-
times be noted several inches above an 
intravenous site through which the drug 
has been infused. These effects tend to be 
delayed, sometimes becoming apparent 
one to three weeks after treatment, and 
can last indefinitely. Clinical data with 
paclitaxel extravasation appears to cause 
minimal long-term effects, although pa-
tients can experience pain, edema, and 
erythema at the site fol lowed by a brawny 
(rough) appearance of the skin. 
In a recent report where pad itaxel 250 
mg/m2 was infused through peripheral 
intravenous access over 24 hours, three 
out of 24 patients developed grade 2 
severity skin reactions based on the Com-
mon Toxicity Criteria developed by the 
NCI. In one patient, histopathologic evi-
dence of marked soft-tissue necrosis w 
documented. This report suggested tha~ 
paclitaxel is a vesicant and that the seve~~ 
ity of the soft-tissue injury should be clas. 
sified as moderate. Additionally, this 
dr.ug also appears to cause delayed soft. 
tissue reactions such as those that have 
been observed with vinblastine. All pa. 
tients receiving paclitaxel should be rnon. 
itored for extravasation. 
Treatment options for paclitaxel 
extravasation are not well documented 
and the role of hyaluronidase is unknown'. 
A protocol presently used by The Johns 
Hopkins Oncology Center recommends 
close observation and minimization of 
the amount of drug extravasated by aspi-
ration before removing the intravenous 
catheter. Following removal of the cath-
eter, warm compresses are applied to the 
extravasation site for 24 hours. lntrader-
mal infiltration of the site with normal 
saline to dilute paclitaxel in the tissue 
does not appear to increase effectiveness. 
There is no data available to indicate any 
difference inthe incidenceofextravasation 
between the three-hour and the 24-hour 
infusions. 
Conclusion 
Current data indicates that a three-
hour infusion of high-dose paclitaxel is 
safe, well-tolerated and does not result in 
a higher incidence of hypersensitivity re-
actions than the 24-hour infusion. No 
unexpected side effects or toxicities were 
observed, with the possible exception of 
arthralgias and myalgias. If proper 
premedications and monitoring are pro-
vided, paclitaxel can be safely adminis-
tered via a shorter infusion time in an 
outpatient setting, resulting in consider-
able cost savings and improvement in 
convenience for patients. 
Dr. Wong is an Oncology Pharmacist 
Specialist at the University of California 
Irvine Medical Center in Orange. 
Editor's Note: References are available 
upon request. 
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